Sunpointe’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-5,919
Closed -$361K 237
2025
Q1
$361K Sell
5,919
-479
-7% -$27.9K 0.19% 103
2024
Q4
$362K Buy
6,398
+1,040
+19% +$58.1K 0.18% 107
2024
Q3
$277K Buy
5,358
+247
+5% +$11.6K 0.23% 111
2024
Q2
$212K Buy
5,111
+953
+23% +$42.6K 0.14% 147
2024
Q1
$225K Buy
+4,158
New +$212K 0.25% 120

Other funds holding BMY

Sunpointe's BMY Position: Q2 2025 in Review

Sunpointe sold out of Bristol-Myers Squibb (BMY) in Q2 2025, closing a stake of 5,919 shares — an estimated $361K sold.

Sunpointe first reported a position in BMY in Q1 2024 and held it in 5 quarters. The position peaked at $362K in Q4 2024. 2,292 funds tracked by Wall St. Rank hold BMY as of Q2 2025.

  • Sunpointe reported no remaining Bristol-Myers Squibb position as of Q2 2025 after selling out during the quarter.
  • Sunpointe sold 5,919 Bristol-Myers Squibb shares in Q2 2025, an estimated $361K.
  • Sunpointe first reported a position in Bristol-Myers Squibb in Q1 2024 and held it in 5 quarters.
  • Sunpointe's Bristol-Myers Squibb position peaked at $362K in Q4 2024.
  • 2,292 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2025.

Based on Sunpointe's 13F filing for Q2 2025, filed 9 Jul 2025.